Publications émanant des bourses de recherche dans le cadre du GFRS :

Année 2011:

Autologous HSCT in systemic sclerosis: a step forward. Farge D, Gluckman E.
Lancet 2011; 460-2.

Mood and anxiety disorders in systemic sclerosis patients. Baubet T, Ranque B, Taïeb O et al
Presse med 2011; 40: e 111-9.

Association of gender with clinical expression, quality of life, disability and depression and anxiety in patients with systemic sclerosis. Nguyen C, Bérezné A, Baubet T.
PLoS One 2011; e 17551.

Association of Fcy receptor IIIA variant with a subset of anti-topoisomerase I-positive patients in systemic’s pilot study. Magnant J, Ohresser M, Allanore Y et al.
Rheumatol Int 2011; 29: S6-9.

IgG from patients with pulmonary arterial hypertension and/or systemic sclerosis binds to vascular smooth muscle cells and induces cell contraction. Bussone G, Tamby MC, Calzas C et al.
Ann Rheum Dis 2011; Nov 14 (Epub ahead of print).

Targets of anti-endothelial cell antibodies in pulmonary hypertension and scleroderma. Dib H, Tamby MC, Bussone G et al.
Eur Respir J 2011; Oct 20. (Epub ahead of print).

Identification of target antigens of anti-endothelial cell and anti-vascular smooth muscle cell antibodies in patients with geant cell arteritis, a proteomic approach. Regent A, Dib H, Ly KH et al.
Arthrits Res Ther 2011; 13: R74.

Increased frequency of circulating Th 22 in addition to Th 17 and Th2 lymphocyts in systemic sclerosis: association with interstitial lung disease. Truchetet ME, Brambilla NC, Montanari E et al.
Arthritis Res Ther 2011; 13: R166.

A genetic variant located in the promoter region of the UPAR (CD 87) gene is associated with the vascular complications of systemic sclerosis. Manetti M, Allanore Y, Revillard l et al.
Arthritis Rheum 2011; 63: 247-56.

Année 2010:

Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosis. Baraut J, Michel L, Verrecchia F et al.
Autoimmun Rev 2010; 10: 65-73.

Association of the TNFAIP3 rs 5029939 variant with systemic sclerosis in the European Caucasian population. Dieudé P, Guedj M, Wipff J et al.
Ann Rheum Dis 2010; 69: 1958-64.

Antifibroblast antibodies from systemic sclerosis patients bind to (alpha)-enolase and are associated with interstitial lung disease. Terrier B, Tamby MC, Camoin L et al.
Ann Rheum Dis 2010; 69: 428-33.

Association of metalloprotease gene polymorphism and systemic sclerosis: a new perspective for the European Caucasian population. Wipff J, Dieudé P, Avouac J et al.
J Rheumatol 2010; 37: 599-602.

Oral sildenafil increases skin hyperaemia induced by ionophoresis of sodium nitroprusside in healthy volunteers. Blaise S, Hellmann M, Roustit M et al.
Br J Pharmacol 2010 ; 106 : 1128-34.

Association study of serotonin transporter gene (SLC6A4) in systemic sclerosis in European Caucasian population. Wipff J, Bonnet P, Ruiz B et al.
Rhumatol 2010; 37: 1164-7.

Increased alveolar concentration of nitric oxide is related to serum-induced lung fibroblast proliferation in patients with systemic sclerosis. Hua-Huy T, Tiev KP, Chereau C et al.
J Rheumatol 2010; 37: 1680-7.

Association of KCNAS gene polymorphism with systemic sclerosis –associated pulmonary arterial hypertension in the European Caucasian population. Wipff J, Dieudé P, Guegj M et al.
Arthritis Rheum 2010; 62: 3093-110.

Inactivation of the transcription factor STAT4 prevents inflammation-driven fibrosis in systemic sclerosis animals models. Avouac J, Fürnrohr BG, Tomcik M et al.
Arthritis Rheum 2010; Dec 15.

New onset of myasthenia gravis after treatment of systemic sclerosis autologous hematopoietic stem cell transplantation: sustained autoimmunity or inadequate reset of tolerance? Deligny C, Clave E, Sibon D et al.
Hum Immunol 2010; 363-5.

Dermal tissue and cellular expression of fibrillin 1 in diffuse cutaneous systemic sclerosis. Wipff J, Avouac J, Le Charpentier M et al.
Rheumatology 2010; 49: 657-61.

Année 2009:

The transport of high amounts of vascular endothelial grouth factor by blood platelets underlines their potential contribution in systemic sclerosis angiogenesis. Solanilla A, Villeneuve J, Auguste P.
Rheumatology 2009; 48: 1036-44.

Bank 1 is a genetic risk factor for diffuse cutaneous systemic sclerosis and has additive effects with IRF5 and STAT4. Dieudé P, Wipff J, Guedj M et al.

Arthritis Rheum 2009; 60: 3447-54.

STAT4 is a genetic risk factor for systemic sclerosis having effects with IRF5 on disease susceptibility and related pulmonary fibrosis. Dieudé P, Guedj M, Wipff J et al.
Arthritis Rheum 2009; 60: 2472-9.

Male microchimerism and HLA compatibility in French woman with scleroderma: a different profile in limited and diffuse subset. Rok JM, Pagni PP, Tiev K et al.
Rheumatology 2009; 48: 363-6.

Association between the IRF5 rs 2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis. Dieudé P, Guedj M, Wipff J et al.
Arthritis Rheum 2009; 60: 225-33.

A large multicenter analysis of CTGF-945 promoter polymorphism does not confirm association with systemic sclerosis susceptibility or phenotype. Rueda B, Simeon C, Husselstrand R et al.
Ann Rheum Dis 2009; 68: 1618-20.

Evidence of an antifibrotic affect of immunosuppressive drugs: applications in the treatment of systemic sclerosis. Verrecchia F, Wang Y, Vijo L.
Expert Rev Clin Immunol 2009; 5: 35-43.

Année 2008:

Angiogenesis in systemic sclerosis: impaired expression of vascular endothelial grouth factor receptor in endothelial progenitor-derived cells under hypoxic conditions. Avouac J, Wipff J, Goldman O et al.
Arthritis Rheum 2008; 58: 3350-61.

Circulating endothelial progenitor cells in systemic sclerosis: association with disease severity. Avouac J, Juin F, Wipff J et al.
Ann Rheul Dis 2008; 67: 1455-60.

Long-term follow-up results after autologous haematopietic stem cell transplantation for severe systemic sclerosis. Vank MC, Marjanovic Z, van den Hoogen GH et al.
Ann Rheum Dis 2008; 67: 98-104.

Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open label study. Bérezné A, Ranque B, Valeyre D.
J Rheumatol 2008; 35: 1064-72.

Polymorphic markers of fibrillin-1 gene and systemic sclerosis in European caucasion patients. Wipff J, Giraud M, Sibila J.
J Rheumatol 2008; 35: 643-9.

Identification of target antigens of antifibroblast antibodies in pulmonary arterial hypertension. Terrier B, Tamby mC, Camoin L et al.
Am J Resp Crit Care Med 2008; 15 : 1128-34.

The effect of imatinib (Glivec) on scleroderma and normal dermal fibroblasts: a preclinical study. Soria A, Cario-André M, Lepreux S et al.
Dermatology 2008; 216: 109-17.

Phenotypical and functional characteristics of in vivo expanded bone marrow mesenchymal stem cells from patients with systemic sclerosis. Larghero J, Farge D, Broccini A et al.
Ann Rheum Dis 2008; 67: 443-9.

Année 2007:

Immunoblotting on HEP-2 cells increases the detection of antitopoisomerase-1 antibodies in patients with systemic sclerosis. Tamby MC, Servettaz A, Guilpain P et al.
Clin Immunol 2007; 123: 82-8.

Antitopoisomerase-1 antibodies in systemic sclerosis: how to improve the detection? Tamby MC, Bussone G, Mouthon L et al.
Ann N Y Acad Sci 2007; 1109: 221-8.

Levels of circulating endothelial progenitor cells in systemic sclerosis. Allanore Y, Batteux F, Avouac J et al.
Clin Exp Rheumatol 2007; 25: 60-6.

Association between an endoglin gene polymorphism and systemic sclerosis-related pulmonary arterial hypertension. Wipff J, Kahan A, Hachulla E et al.
Rheumatology 2007; 46: 622-5.

Involvement of ERK signaling on halofuginone-driven inhibition of fibroblast ability to contract collagen lattices. Tacheau C, Michel L, Farge D et al.
Eur J Pharmacol 2007; 573: 65-9.

Année 2006:

IL13RA2 gene polymorphisms are associated with systemic sclerosis. Granel B, Allanore Y, Chevillard C et al.
Rheumatol 2006; 33: 2015-9.

Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension. Tamby MC, Humbert M, Guilpain P et al.
Eur Respir J 2006; 28: 799-807.

Post-occlusive reactive hyperemia inversely correlates with urinary 15-F2t-isoprostane levels in systemic sclerosis. Cracowki JL, Kom GD,  Salvat-Melis M et al.
Free Radic Biol Med 2006; 40: 1732-7.

Evaluation of interleukin 13 polymorphisms in systemic sclerosis. Granel B, Chevillard C, Allanore Y.
Immunogenetics 2006; 58: 693-9.

Proteasone blockade exerts an antifibrotic activity by coordinately down-regulating type 1 collagen and tissue inhibitor of metalloprotease-1 and up-regulating metalloprotease-1 production in human dermal fibroblasts.  Fineschi S, Reith W, Guerne PA.
FASEB 2006; 20: 562-4.

Digital thermal hyperhemia impairment does not relate to skin fibrosis or macrovascular disease in systemic sclerosis. Salvat-Melis M, Carpentier Ph, Minson CT et al.
Rheumatology 2006; 45: 1590-6.

Modulation of collagen and MMP-1 gene expression in fibroblasts by the immunosuppressive drug rapamicin-A direct role as an antifibrotic agent? Pouldhon N, Farge D, Roos N.
J Biol Chem 2006; 281: 33045-52.

Transforming grouth-factor-beta signaling through the Smad proteins: role of systemic sclerosis. Verrecchia F, Mauviel A, Farge D et al.
Autoimmun Rev 2006; 5: 563-9.

Année 2005:

Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Gottemberg JE, Guillevin L, Lambotte O et al.
Ann Rheum Dis 2005; 64: 913-20.

Validation of French version of the Scleroderma Health Assessment Questionaire (SSc HAQ). Georges  C, Chassagny O, Mouthon L et al.
Clin Rheumatol 2005; 3-10.

Therapeutic intensification and autologous stem cell transplantation in autoimmune diseases. Marianovic Z, Gerber I, Toledano C et al.
Presse Med 2005; 34: 311-8.

Effects of short-time treatment with vitamin E in systemic sclerosis: a double blind, randomized controlled clinical trial of effect based on urinary isoprostane measurement. Cracowki JL, Girolet S, Imbert B et al
Free Radic Biol Med 2005; 38: 98-103.

Local hyperhemia to heating is impaired in secondary Raynaud phenomenon. Boignard A, Salvat-Melis M, Carpentier Ph.
Arthritis Res Ther 2005; 7: R1103-12.

Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated with pulmonary arterial hypertension. Tamby MC, Chanseaud Y, Humbert M et al.
Thorax 2005; 60: 765-72.

Année 2004:

Maitre A, Hours M, Bonneterre V et al. Systemic sclerosis and occupational risk factors: role of solvents and cleaning products.
J Rheumatol 2004; 31: 2395-401.

Nifedipine decreases sV CAM-1 concentrations and oxidative stress in systemic sclerosis but does not affect the concentrations of vascular endothelial growth factor or its soluble receptor 1. Allanore Y, Borderie O, Lemaréchal H et al.
Arthritis Res Ther 2004; 6: R309-14.

Acute and sustained effects of dihydropyridine-type calcium channel antagonists on oxidative stress in systemic sclerosis. Allanore Y, Borderie O, Lemaréchal H et al.
Am J Med 2004; 116: 595-600.

IgG reactivity with a 1000-kDA tissue and endothelial cell antigen identified as topoisomerase-1 distinguishes between limited and diffuse systemic sclerosis patients. Garcia de la Penä-Lefebvre P, Chanseaud Y, Tamby Mc et al.
Clin Immunol 2004; 111: 211-15.